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Abstract
Background: Obesity, insulin resistance and hyperandrogenism, crucial parameters of Polycystic ovary syndrome
(PCOS) play significant pathophysiological roles in lipidemic aberrations associated within the syndrome. Parts of
the metabolic syndrome (low HDL and insulin resistance) appeared to facilitate the association between PCOS and
coronary artery disease, independently of obesity. ABCA1 gene polymorphism may be altered this components in
PCOS patients.
In this study, we studied 98 PCOS patients and 93 healthy controls. All subjects underwent venous blood drawing
for complete hormonal assays, lipid profile, glucose, insulin, malondialdehyde, nitric oxide, disulfide levels and ABCA
genetic study.
Results: In PCOS group fasting glucose, DHEAS, 17-OHP, free testosterone, total-cholesterol, triglyceride, LDL-
cholesterol and fibrinogen were significantly different compare to controls. The genotype ABCA G2706A
distribution differed between the control group (GG 60.7%, GA 32.1%, AA 7.1%) and the PCOS patients (GG 8.7%,
GA 8.7%, AA 76.8%). The frequency of the A allele (ABCAG2706A) was higher in PCOS patients than control group
with 13,0% and 23,2%, respectively. In this study, the homocystein and insulin levels were significantly higher in
PCOS patients with ABCA G1051A mutant genotype than those with heterozygote and wild genotypes.
Conclusions: We found higher percentage of AA genotype and A allele of ABCA G2706A in PCOS patients
compare to controls. The fasting insulin and homocystein levels were significantly higher in PCOS patients with
ABCA G1051A mutant genotype than those with heterozygote and wild genotypes.
Introduction
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine diseases and typically presents with
chronic anovulation and hyperandrogenism [1]. PCOS is
a common endocrine disorder, affecting between 4% and
8% of the women of reproductive age [2]. PCOS usually
arises during puberty and is marked by hyperinsulinemia
and hyperandrogenism. Adolescents with PCOS have an
increased risk of developing health problems later on in
life such as type 2 diabetes, cardiovascular disease, and
infertility [3]. Studies suggest that PCOS is associated
with increased risk of coronary heart disease (CHD) [4].
Elevated plasma Hcy levels and oxidative stress para-
meters are considered as an independent risk factor for
CVD [5-7].
Dyslipidemia is possibly the most common metabolic
abnormality of PCOS, although the findings of relevant
studies have been variable and a substantial percentage of
women with PCOS might still have normal lipid profiles * Correspondence: muammermd@hotmail.com
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described in PCOS [9].
Obesity, IR and hyperandrogenism, crucial parameters
of PCOS play significant pathophysiological roles in lipi-
demic aberrations associated with the syndrome. IR repre-
sents another key factor implicated in the dyslipidemia of
PCOS. Glueck et al. reported that 46% of women with
PCOS suffered from the metabolic syndrome. Within this
subgroup of women, lipid abnormalities were found to be
extremely common. 95% of these women demonstrated
decreased levels of high-density-lipoprotein (HDL),
whereas 56% had hypertriglyceridemia [10].
Lean women with PCOS were shown to have
decreased HDL and HDL2 levels when compared to
women with normal ovarian function, whereas obese
PCOS women also had elevated triglyceride levels [11].
Hyperlipidemia was frequently connected with the disor-
ders in apolipoproteins, receptors, enzymes, or cofactors in
proteins related to lipoprotein metabolism. The changes
happened in ABCA1 gene can play an important role
amongst these changes. ABCA1 gene was considered to
be responsible for the cause of Tangier disease [12].
Luciani and collagues were defined ABC transporter
family for the first time in 1994. ATP-binding cassette
(ABC) genes encode a large family of transmembrane pro-
teins. These proteins bind ATP in order to control the
transition of different molecules (such as cholesterol) from
cell membranes [13].
This study aims at exploring the association between
metabolic, oxidative stress parameters (including malon-
dialdehyde, (MDA) nitric oxide (NO) and disulfide levels
(SH)) and demographic parameters and ABCA1 gene
polymorphisms in polycystic ovary syndrome patients.
Materials and methods
Patients
In this study, we studied 98 PCOS patients and 93
healthy controls. All researchs with human samples were
done with written informed consent of the patients and
with approval of the ethical committee of the Ege Uni-
versty Hospital. The patients had been referred to the
Endocrinology and Metabolism Disease outpatient clinic
at the Ege University Hospital. PCOS was defined by the
Rotterdam PCOS consensus criteria [14]. Patients who
had DM, hyperprolactinemia, congenital adrenal hyper-
plasia (diagnosed with the adrenocorticotropic hormone
stimulation test), thyroid disorders, Cushing’ss y n d r o m e ,
hypertension, hepatic or renal dysfunction were excluded
from the study. Confounding medications, including oral
contraceptive agents, hypertensive medications and insu-
lin-sensitizing drugs, and those which may affect the
metabolic criteria were questioned. Another 93 healthy
young volunteer females matched for age, body mass
index (BMI), and allele frequency were included from the
study, and considered as the control group. Their health
state was determined by medical history, physical and
pelvic examination, and complete blood chemistry. The
patients with PCOS and the control group were geneti-
cally unrelated.
Study protocol
At study entry, all subjects underwent venous blood
drawing for complete hormonal assays, lipid profile, glu-
cose, insulin and ABCA genetic study. All blood samples
were obtained in the morning between 08.00 and 09.00
hours after an overnight fasting, and resting in bed dur-
ing early follicular phase of the spontaneous or P-induced
menstrual cycle. During the same visit, all subjects under-
went anthropometric measurements including BMI and
detail history, systolic and diastolic blood pressure. In
present study, data related to the serum malondialde-
hyde, nitric oxide and disulfide levels, homocystein and
fibrinogen levels and the genetic evaluation of ABCA will
be shown and discussed.
Biochemical assay
Serum total cholesterol, LDL and HDL cholesterol were
measured by Olympus AU 2700 automated analyzer.
Plasma insulin concentrations were determined by
Immunolite 2000 using two-site chemiluminescent
immunometric assay.
Methods for plasma MDA, NO, total sulfhydryl group
measurements
All reagents were purchased from Sigma and Merck.
MDA was determined by a modified spectrophometric
method of Yagi K [15] using tetrametoxypropan as Stan-
dard and BioTek MicroQuant microplate reader. NO was
determined by measuring stable NO end-products-nitrite
and nitrate levels using Miranda’s spectrophometric
method [16], while total sulfhydryl groups was measured
using Ellman’s reagent by Sedlak and Lindsay’sm e t h o d
[17].
Measurement of plasma homocysteine
Venous blood samples were centrifuged at 1000× g for 10
min and the serums were stored at -80°C until the analy-
sis -not exceeding three months. In this study, serum
total homocysteine levels were measured by Fluorescence
Polarization Immunoassay Method (IMX Homocysteine
Assay, Abbott Diagnostics No: 7D29-20). Dilution
method was used for those whose serum homocysteine
levels were higher than 50 μmol/L. All samples were pre-
pared as 200 μl. Three controls were used in each sample
for calibration of the device. For each of the controls, the
results including ranges were accepted as low control (5,
25-8, 75), medium control (10.0-15.0), and high control
(20.0-30.0) μmol/ml.
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DNA isolations were carried out by using High Pure PCR
Template Preparation Kit (Roche Applied Science, Ger-
many) from peripheral blood samples of control and
study group cases taken to tubes with EDTA.
For ABCA 1 G1051A polymorphism analysis, by using
Forward Primer: 5’-CTC CAA AAGACT TCA AGG ACC
C-3’, Reverse Primer: 5’-GGC CCA AAA GTC TGA AAG
AAC AC-3’ primer pair, a DNA fragment of 433 base
pairs is amplified by PCR method. For each sample, 25 μl
of prepared PCR reaction mixture contains 16, 75 μlo f
sterile distilled water, 0,5 μl of Forward primer (100 p μl),
0,5 μl of Reverse primer (100 p μl), 2,5 μlM g
+2 (25 mM),
2 μl of dNTP mixture (2 mM), 0,25 μl of Taq DNA poly-
merase (5 U/μl), and 2,5 μl of genomic DNA.
i - PCR amplification
Denaturation is carried out at 95°C for 2 minutes, ampli-
fication at 94°C for 30 seconds as 35 cycles, 1 minute at
72°C, prolongation at 72°C for 7 minutes by applying
PCR protocol.
For ABCA1 G2706A polymorphism analysis, DNA frag-
ment of 350 base pairs is amplified by using Forward Pri-
mer: 5’-CAA GTG AGT GCT TGG GAT TG-3’, Reverse
Primer: 5’-TGC TTT TAT TCA GGG ACT CCA-3’ pri-
mer pairs by PCR method. For each sample, 25 μl of PCR
reaction mixture contains 17, 25 μl of sterile distilled
water, 0,5 μl of Forward primer (100 p μl), 0,5 μlo f
Reverse primer (100 p μl), 2,5 μlM g
+2 (25 mM), 1,5 μlo f
dNTP mixture (2 mM), 0,25 μl of Taq DNA polymerase
(5 U/μl), and 2,5 μl of genomic DNA.
ii - PCR amplification
Denaturation is carried out for ten minutes at 94°, amplifi-
cation for 30 seconds at 94°C as 40 cycles, for 45 seconds
at 52°C, 1 minutes at 72°C, prolongation for 7 minutes at
72°C by applying PCR protocol. The size of the products
obtained after PCR is controlled at gel electrophoresis.
PCR products made for the analysis of ABCA 1 G1051A
and G2706A gene polymorphisms are evaluated in agarose
gel of 2%.
G1051A polymorphism analysis of -ABCA 1 gene is car-
ried out at 37°C for 6 hours by incubating RFLP reaction
mixture of 30 μlc o n t a i n i n g1 7μl of distilled water, 10 μl
of PCR product, 2 μl of Buffer O, and 1 μl of EcoO109I
enzyme.
G2706A polymorphism analysis of -ABCA 1 gene is car-
ried out by incubating at 30°C for 3 hours the mixture of
RFLP reaction of 30 μl containing 17 μl of distilled water,
10 μl of PCR product, 2 μl of Buffer O, and 1 μl of BsaAI
enzyme.
Genotyping is carried out after having conducted and
displayed the products obtained as a result of enzyme cut
for G1051A polymorphism analysis of ABCA 1 gene in
agarose gel of 2% and in agarose gel of 3% for G2706A
polymorphism analysis.
As a result of G1051A polymorphism analysis, DNA
fragments of sizes of 189 base pairs, 131 base pairs, and
113 base pairs in cases of wild genotype, 320 base pairs,
189 base pairs, 131 and 113 base pairs in heterozygote
cases, and 320 base pairs and 113 base pairs in mutant
cases are obtained (Figure 1). As a result of G2706A poly-
morphism analysis, DNA fragments of sizes of 252 base
pairs and 98 base pairs in cases of wild genotype, 350 base
pairs, 252 base pairs and 98 base pairs in heterozygote
cases, and 350 base pairs in mutant cases are obtained
(Figure 2).
Results
I-Demographic, metabolic and oxidative stress
parameters of patients and controls
The demographic, hormonal and metabolic parameters
of the PCOS and control groups are shown in Table 1. In
the PCOS group fasting glucose, DHEAS, 17-OHP, free
testosterone, total-cholesterol, triglyceride, LDL-choles-
terol and fibrinogen were significantly (P < 0.05) different
in comparison with healthy women (Table 1). The fasting
glucose levels were significantly (P < 0.05) higher in
PCOS than in control women, whereas no difference was
observed in fasting insulin concentrations between the
groups (Table 1). No significant differences were detected
in age, weight, BMI, homocystein, MDA, NO, SH,
 
 
 
 
320 bp 
189 bp 
131 bp 
113 bp 
Figure 1 RFLP patterns of ABCA1 G1051A gene obtained with
StyI restriction endonuclease. Lane1. 50 bp DNA ladder
(Fermentas); Lane2. GG genotype; Lane3. AA genotype; Lanes
4,5,6,7,8,9. GA genotypes.
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between two groups (Table 1).
II-Allelic distributions and ABCA genotype frequencies in
patients
The frequency of ABCA G1051A and G2706A poly-
morphism are shown in Table 2. The allelic distribution
of ABCA genotypes was in Hardy-Weinberg equilibrium
for both groups of women.
The genotype ABCA G1051A distribution didn’t differ
between the control group (GG 31.2%, AG 53.8%, AA
15.1%) and the PCOS patients (GG 36.6%, AG 52.7%, AA
10.8%) (P > 0.05) The genotype ABCA G2706A distribu-
tion differed between the control group (GG 60.7%, GA
32.1%, AA 7.1%) and the PCOS patients (GG 8.7%, GA
8.7%, AA 76.8%) (P < 0.05). The frequency of the poly-
morphic A allele (ABCA G2706A) was higher in PCOS
patients than control group with 13,0% and 23,2%, respec-
tively (p = 0.027, OR:2.016; Table 2).
III-Effects of ABCA genotypes on lipid profile,
demographic and other metabolic parameters in patients
There was no statistically significant difference in PCOS
patients between ABCA G1051A genotypes (AA, GA and
GG) and BMI, fasting insulin, fasting glucose, triglyceride
levels, HDL levels, LDL levels, fasting blood glucose levels,
f-testosterone, fibrinogen and 17-OHP levels (p > 0.05;
Table 3). The fasting insulin level was significantly higher
in PCOS patients with ABCA G1051A mutant genotype
than those with heterozygote and wild genotypes (Table 3).
No statistically meaningful difference was determined
between polymorphism and lipid and other parameter
levels in patients carrying ABCA1 G2706A polymorphism
(Table 4).
IV-Effects of ABCA genotypes on oxidative stress markers,
homocystein levels in patients
In our study, the homocystein levels were significantly
higher in PCOS patients with ABCA G1051A mutant
genotype than those with heterozygote and wild geno-
types (Table 3). The ABCA genotypes do not appear to
have significant correlation with the plasma Hcy levels,
MDA, NO and SH in PCOS patients.
Discussion
Women with PCOS have multiple risk factors for the
development of cardiovascular disease, including hyperan-
drogenemia, insulin resistance and glucose intolerance,
obesity, and central fat deposition [18]. Women with
PCOS are also at increased risk for the development of the
metabolic syndrome [19,20].
Additionally, different markers of clinical and subclini-
cal atherosclerosis, including serum markers (for example
fibrinogen, high sensitive C-reactive protein and homo-
cysteine, oxidative stress markers, PAI-1, TPA), carotid
intimae-media thickness, and echocardiographic findings
have also been found to be changed [21-25]. In our
350 bp 
252 bp 
98 bp 
Figure 2 RFLP patterns of ABCA1 G2706A gene obtained with
BasaI restriction endonuclease. Lane1. 50 bp DNA ladder
(Fermentas); Lanes 2, 4,5,6,8 GA genotypes; Lanes 3, 7 GG
genotypes.
Table 1 Clinical characteristics of patients and controls
Control Group PCOS Group p
Mean ± SD Mean ± SD
Age (years) 25,63 7,67 24,44 5,69 0,567
Weight 60,43 15,37 66,17 16,08 0,099
BMI (k/m
2) 24,25 7,68 24,80 5,88 0,436
HCY μmol/ml. 10,90 3,60 12,37 4,05 0,073
MDA (nMol/ml) 6,47 3,63 5,59 2,55 0,396
NO (microMol/L) 8,73 3,04 9,54 4,16 0,595
SH (mMol/L) 6,96 6,07 10,92 7,76 0,172
TAFI 9,89 5,06 12,14 10,01 0,563
Fasting Glucose (mg/dl) 84,39 18,27 91,79 8,99 0,005
Fasting insulin (mIU/ml) 11,09 21,22 15,78 33,23 0,507
Homocysteine (μmol/L) 1,27 1,24 3,83 9,17 0,168
Estradiol (pg/ml) 51,65 58,40 35,13 26,82 0,052
DHEA-S (μg/dl) 272,93 131,36 217,19 115,69 0,035
17 -OHP (ng/ml) 1,10 1,05 1,85 1,04 0,002
Total-Testosterone (ng/ml) 0,92 1,30 0,96 1,85 0,905
Free-Testosterone (pg/ml) 1,76 0,83 3,28 2,12 0,001
Prolactin (pmol) 17,09 10,76 17,01 8,00 0,969
Total-cholesterol (mg/dl) 171,34 61,74 198,95 41,19 0,009
Triglycerides (mg/dl) 88,52 50,83 124,00 69,35 0,014
HDL-C (mg/dl) 59,37 16,39 57,06 15,39 0,514
LDL-C (mg/dl) 98,89 31,83 117,68 31,71 0,01
Fibrinogen (mg/dl) 295,85 102,07 373,83 110,84 0,004
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Polymorphism Genotypes/Haplotypes Control
Group
n=9 3
PCOS
Group
n=9 8
OR* 95% CI* P*
G1051A GG (Wild type) 34
36,6%
30
31,2%
R 0.585
GA (Heterozygote) 49
52,7%
53
53,8%
0,836 0,444-1,574 0,579
AA (Mutant) 10
10,8%
15
15,1%
0,609 0,235-1,577 0,307
G 117
62,9%
114
58,1%
0.817 0.538-1.238 0.396
A6 9
37,1%
82
41,9%
G2706A GG (Wild type) 55
60,7%
80
82,6%
R 0.004
GA (Heterozygote) 30
32,1%
9
8,7%
5,029 1,922-13,160 0.001
AA (Mutant) 8
7,1%
9
8,7%
1,118 0,339-3,685 0.855
G 162
87,0%
150
76,8%
2.016 1.094-3.714 0.027
A2 4
13,0%
46
23,2%
Table 3 Biochemical and Hormonal parameters between ABCA G1051A genotypes in patient group
G1051A Genotype Mean SD 95% CI p
BMI (k/m
2) GG 23,64 5,11 21,62-25,66 0,353
GA 25,45 6,386 23,46-27,44
AA 26,3 6,277 21,81-30,79
Fasting Glucose (mg/dl) GG 91,63 6,264 89,15-94,11 0,291
GA 91,79 7,537 89,44-94,13
AA 96,09 14,883 86,09-106,09
Fasting insulin (mIU/ml) GG 10,2394 4,98809 8,44-12,04 0,001
GA 10,7138 4,53637 9,45-11,97
AA 21,5954 5,05475 8,87-34,32
Homocysteine (μmol/L) GG 2,3526 1,21 1,91-2,79 0,003
GA 2,3925 1,18 2,06-2,72
AA 4.11 3,27 2,04-6,19
Estradiol (pg/ml) GG 29,57 17,069 22,36-36,78 0,226
GA 40,74 33,594 29,69-51,78
AA 29,33 12,952 19,38-39,29
DHEA-S (μg/dl) GG 205,46 90,094 169,07-241,85 0,645
GA 229,45 126,715 188,92-269,98
AA 202,78 112,325 116,44-289,12
17 -OHP (ng/ml) GG 1,878 0,846 1,543-2,212 0,906
GA 1,835 1,2192 1,445-2,225
AA 1,709 0,8723 1,123-2,295
Free-Testosterone (pg/ml) GG 3,16 2,009 2,35-3,97 0,63
GA 3,11 2,248 2,4-3,82
AA 3,8 1,982 2,47-5,13
Total-Testosterone (ng/ml) GG 1,278 3,0116 0,024-2,581 0,582
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NO MDA, and SH levels between patient and control
groups. Fibrinogen levels were found to be statistically
higher in PCOS patients group than the controls. How-
ever, homocystein levels were significantly higher in
PCOS patients with ABCA G1051A mutant genotype
than those with heterozygote and wild genotypes.
Women with PCOS have a higher prevalence and a
greater degree of hyperinsulinemia, and insulin resistance
than weight-matched control subjects [26-28]. However,
in our study, fasting insulin levels were not different from
the controls when compared to healthy controls.
Dyslipidemia is a common metabolic abnormality in
PCOS, although the reported types and extent of lipid
aberrations have been variable [29,30]. PCOS women have
been demonstrated to have substantially higher TC and
LDL levels than control women < 45-years-old, after
adjustment for BMI and hyperinsulinemia [31].
Table 3 Biochemical and Hormonal parameters between ABCA G1051A genotypes in patient group (Continued)
GA 0,748 0,8182 0,458-1,039
AA 0,813 0,2997 0,562-1,063
Prolactin (pmol) GG 17,61 9,731 13,76-21,46 0,568
GA 16,07 7,293 13,67-18,46
AA 18,8 6,125 14,42-23,18
Table 4 Biochemical and Hormonal parameters between G2706A genotypes in PCOS patient group
G2706A Genotype Mean SD 95% CI p
BMI (k/m
2) GG 24,47 5,17 23,01-25,92 0,071
GA 28,42 7,01 21,06-35,77
AA 20,63 1,25 18,64-22,61
Fasting Serum Glucose (mg/dl) GG 92,82 10,28 89,93-95,71 0,691
GA 89,83 6,94 82,55-97,12
AA 90,00 4,32 83,13-96,87
Fasting insulin (mIU/ml) GG 12,5701 10,69 10,04-15,10 0.560
GA 9,6271 4,12 7,25-12,00
AA 11,5217 4,24 8,82-14,22
Homocysteine (μmol/L) GG 2,7138 1,84 2,27-3,15 0.491
GA 2,1653 0,97 1,60-2,73
AA 2,3987 1,21 1,63-3,17
Estradiol (pg/ml) GG 34,72 28,55 26,43-43,01 0,499
GA 45,75 30,71 3,11-94,61
AA 50,50 47,90 25,72-126,72
DHEA-S (μg/dl) GG 216,10 101,88 186,52-245,69 0,079
GA 302,67 156,34 138,60-466,74
AA 148,75 100,73 11,54-309,04
17 -OHP (ng/ml) GG 1,992 1,14 1,664-2,320 0,823
GA 1,767 1,13 0,584-2,950
AA 1,725 0,60 0,767-2,683
Prolactin (pmol) GG 17,20 8,87 14,62-19,77 0,758
GA 15,50 4,28 11,01-19,99
AA 14,50 3,51 8,91-20,09
Free-Testosterone (pg/ml) GG 3,49 2,48 2,77-4,20 0,839
GA 3,92 1,48 2,36-5,47
AA 3,03 1,19 1,13-4,92
Total-Testosterone (ng/ml) GG 1,041 2,32 0,288-1,794 0,671
GA 1,900 1,96 1,224-5,024
AA ,525 0,30 0,050-1,000
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pidemia of PCOS. Glueck et al. reported that 46% of
women with PCOS suffered from the metabolic syndrome
[32]. Within this subgroup of women, lipid abnormalities
were found to be extremely common. 95% of these
women demonstrated decreased levels of high-density-
lipoprotein (HDL), whereas 56% had hypertriglyceridemia.
In this study, no difference was determined in PCOS
patient group in terms of HDL cholesterol when com-
pared to the controls, while TG values were determined to
be statistically meaningfully high in patient group. In this
study, LDL cholesterol and total cholesterol levels were
found to be statistically meaningfully high in PCOS patient
group when compared to the controls.
IR and compensatory hyperinsulinemia are considered
to be main responsible for the lipidemic aberrations of
obesity and PCOS. Besides, genetic factors may also con-
tribute to the formation of dyslipidemia in PCOS disease
[33]. Members of the ATP-binding cassette (ABC) trans-
porter family, such as ABCA1, have been shown to control
cellular lipid metabolism [34,35]. Changes happened in
ATP binding cassette transporter 1 (ABC1) gene encoding
a protein regulating entry and exit from cell membrane
may contribute to dyslipidemia in patients with PCOS.
Jerome I. Rotter et al. found a relation between ABCA1
G1051A polymorphism and HDL-cholesterol elevation.
This relation conflicts with previous studies. Again, these
researchers determined a correlation between ABCA1
G1051A gene polymorphism and moderate LDL-choles-
terol lowness [36,37]. In our study, the genotype ABCA
G1051A distribution didn’t differ between control and
PCOS groups. However, the distribution of ABCA
G2706A genotype differed between the control group and
the PCOS patients. Frikke-Schmidt et al. determined
higher G2706A gene polymorphism allele in patient group
with low HDL cholesterol [38]. In our study, the frequency
of the polymorphic A allele of ABCA G2706A gene was
higher in PCOS patients than control group.
There was no statistically significant difference in
PCOS patients between ABCA G1051A genotypes (AA,
GA and GG) and BMI, fasting insulin, fasting glucose,
triglyceride levels, HDL levels, LDL levels, fasting blood
glucose levels, f-testosterone, fibrinogen and 17-OHP
levels. However, in PCOS patients, fasting insulin levels
and homocystein were found to be significantly higher
in ABCA G1051A mutant genotype than heterozygote
and wild genotypes.
In conclusion, we found AA genotype and A allele of
ABCA G2706A in PCOS patients. The fasting insulin and
homocystein levels were significantly higher in PCOS
patients with ABCA G1051A mutant genotype than
those with heterozygote and wild genotypes. However, it
is determined that ABCA1 G2706A and ABCA G1051A
polymorphisms have no effect on lipid oxidative stress
parameters in patients. Future studies should explain the
specific roles of other genes (e.g CETP, LDL receptor and
hepatic lipase) in the pathophysiology of dyslipidemias in
PCOS.
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